Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1999-04-28
2003-09-02
Jones, W. Gary (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S023100, C536S024300
Reexamination Certificate
active
06613510
ABSTRACT:
TECHNICAL FIELD
The invention relates to a method for determining prostate cancer prognosis.
BACKGROUND OF THE INVENTION
Prostate cancer represents the most common malignancy in men, and was estimated to result in approximately 39,000 related deaths in 1998 in the United States. Up to about 59% of prostate cancer cases present as a localized tumor, i.e., stages A and B, where the tumor is confined to the prostate. Clinical stage C, in which the tumor is clinically localized to the periprostatic area, but extends through the prostatic capsule and may involve seminal vesicles, represents about 14% to 18% of cases. The remaining 10% to 18% of cases are metastatic or clinical stage D.
In general, clinically aggressive behavior is associated with an accumulation of genetic aberrations in some solid tumors, such as colon cancer and urinary bladder cancer. Similar multiple genetic changes also may occur in prostate carcinoma. As prostatic cancer is a leading cause of death of males in the United States, the identification of patients whose tumor is destined to progress rapidly is a major goal of current research. Unfortunately, within a cohort of men with a single grade and stage of prostate cancer, there are few markers of clinical aggressiveness.
SUMMARY OF THE INVENTION
The invention is based, in part, on the discovery that assessing loss or gain of the 8p locus of chromosome 8, the centromere of chromosome 8, and the 8q24 locus provides a prognostic indicator for prostate cancer. Assessing the combined hybridization pattern of these markers provides a sensitive method for determining prostate cancer progression and prognosis, and leads to earlier treatment in certain cases.
In one aspect, the invention features a method for determining prostate cancer prognosis in a subject that includes determining a hybridization pattern of a set of chromosomal probes in a biological sample from the subject. The chromosomal probe set includes a probe to the 8p locus of chromosome 8 and a probe to the 8q24 locus of chromosome 8, and further can include a probe to the centromere of chromosome 8. The 8p locus can be defined further as 8p21-22 and the 8q24 locus can be defined further as the c-myc gene. The biological sample can be selected from the group consisting of prostate tissue resections, prostate tissue biopsies, urine, and bladder washings. Prostate tissue biopsies are particularly useful.
Prognosis of the subject is determined to be poor when the hybridization pattern indicates loss of the 8p locus, gain of chromosome 8, and additional increase of c-myc copy number relative to centromere copy number. Hybridization pattern can be determined by hybridizing the set of chromosomal probes to the biological sample and detecting the presence or absence of hybridized probe. The probes can be labeled, e.g. fluorescently labeled.
The invention also features a kit for determining cancer prognosis in a subject. The kit includes a set of chromosomal probes, which includes a probe to the 8p locus of chromosome 8 and a probe to the 8q24 locus of chromosome 8, and further can include a probe to the centromere of chromosome 8. The 8p locus can be defined further as 8p21-22 and the 8q24 locus can be defined further as the c-myc gene. The probes can be labeled, e.g. fluorescently labeled. The kit further can include instructions that indicate prognosis is determined to be poor when a hybridization pattern of the set of chromosomal probes indicates loss of the 8p locus, gain of chromosome 8, and additional increase of c-myc copy number relative to centromere copy number.
Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
REFERENCES:
patent: 5447841 (1995-09-01), Gray et al.
patent: 5491224 (1996-02-01), Bittner et al.
patent: 5658730 (1997-08-01), McGill et al.
patent: 5776688 (1998-07-01), Bittner et al.
patent: 5856089 (1999-01-01), Wang et al.
patent: 5882864 (1999-03-01), An et al.
patent: 5925519 (1999-07-01), Jensen et al.
patent: WO 96/20288 (1996-07-01), None
Bova et al. “Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer”. Cancer Research, vol. 53, No. 17, pp. 3869-3873, Sep. 1993.*
Jenkins et al. “Prognostic significanc of allelic imbalance of chromosome arms 7q, 8p, 16q and 18q in stage T3N0M0 prostate cancer” Genets, Chromosome, and Cancer, vol. 21, p. 131-143, Feb. 1998.*
Van Den Berg et al. “DNA sequence amplfiication in human prostate cancer identified by chromosome microdissection: potential prognostic implications” Clinical Cancer Research, vol. 1, p. 11-18, Jan. 1995.*
Bova et al “Review of allelic loss and gain in prostate cancer” World J. Urol, vol. 14, p. 338-346, Oct. 1996.*
Nupponene et al “Genetic Alterations in hormone-refractory recurrent prostate carcinomas” Am. J. of Pathology, vol. 153, No. 1, p. 141-148, Jul. 1998.*
Visakorpi et al “Genetic Changes in primary and recurrent prostate cancer by CGH” Cancer Research, vol. 55, p. 342-347, 1995.*
Wheeless et al., “Bladder Irrigation Specimens Assayed by Fluorescence In Situ Hybridization to Interphase Nuclei”,Cytometry, 1994, 17(4):319-326.
Nath et al., “Fluorescence in Situ Hybridization (FISH): DNA Probe Production and Hybridization Criteria”,Biotechnic Histochem., 1997, 73(1):6-22.
Florentine et al., “Detection of Hyperdiploid Malignant Cells in Body Cavity Effusions by Fluorescence In Situ Hybridization on ThinPrep Slides”,Cancer, 1997, 81(5):299-308.
Cher et al., “Comparative Genomic Hybridization, Allelic Imbalance, and Fluorescence In Situ Hybridization on Chromosome 8 in Prostate Cancer”,Genes, Chromosomes Cancer, 1994, 11:153-162.
Reiter et al., “Prostate stem cell antigen: A cell surface marker overexpresssed in prostate cancer”,Proc. Natl. Acad. Sci. USA, 1998, 95(4):1735-1740.
Steiner et al., “Antisense c-myc Retroviral Vector Suppresses Established Human Prostate Cancer”,Hum. Gene Ther., 1998, 9(5):747-755.
Jenkins et al., “Prognostic Significance of Allelic Imbalance of Chromosome Arms 7q, 8p, 16q, and 18q in Stage T3N0M0Prostate Cancer”,Genes, Chromosomes Cancer, 1998, 21:131-143.
Persons et al., “Use of Fluorescent In Situ Hybridization for Deoxyribonucleic Acid Ploidy Analysis of Prostatic Adenocarcinoma”J. Urol., 1993, 150(1):120-125.
Cheville et al., “Expression of p27kip1in Prostatic Adenocarcinoma”,Mod. Pathol., 1998, 11(4):324-328.
Jenkins et al., “Detection of c-myc Oncogene Amplification and Chromosomal Anomalies in Metastatic Prostatic Carcinoma by Fluorescence in Situ Hybridization”,Cancer Res., 1997, 57:524-531.
Zojer et al., “Chromosomal imbalances in primary and metastatic pancreatic carcinoma as detected by interphase cytogenetics: basic findings and clinical aspects”,Brit. J. Cancer, 1998, 77(8):1337-1342.
Mark et al., “Fluorescent in Situ Hybridization Study of c-myc Oncogene Copy Number in Prostate Cancer,”Exp. Mol. Pathol., 2000, 68:65-69.
Sato et al., “Clinical Significance of Alterations of Chromosome 8 in High-Grade, Advanced, Nonmetastatic Prostate Carcinoma,”J. Natl. Cancer Inst., 1999, 91(18):1574-1580.
Wolff et al., “Oral squamous cell carcinomas are charaterized by a rather uniform pattern of genomic imbalances detected by comparative genomic hybridisation,”Oral Oncology, 1998, 34:186-190.
Jenkins Robert B.
Qian Junqi
Sato Kazunari
Fish & Richardson P.C. P.A.
Goldberg Jeanine
Jones W. Gary
Mayo Foundation for Medical Education and Research
LandOfFree
Methods and probe sets for determining prostate cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and probe sets for determining prostate cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and probe sets for determining prostate cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3091701